Breaking
European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
🇪🇺 EMA
🇪🇺 Europe · Directory profile

Abcam

Abcam | Antibodies, Assays & Research Reagents for Drug Discovery

Visit website

Overview

Abcam is a life sciences company established in 1998 that provides highly validated antibodies, assays, proteins, and research reagents to support drug discovery, diagnostics, and basic research. The company serves 750,000 researchers across 130+ countries and offers full-cycle support from antibody identification and development through validation, pre-clinical selection, and commercialization. Abcam specializes in delivering well-characterized proteins and reagents targeting critical biological pathways in cancer, neurological disorders, infectious diseases, and metabolic disorders. Now operating as part of Danaher's Life Sciences segment, Abcam continues to provide expert scientific support and data-driven expertise in antibody discovery and production.

Frequently asked questions

What products and services does Abcam offer for drug discovery?
Abcam provides antibodies, assays, proteins, lysates, tissue slides, and other research reagents. The company offers full-cycle support including antibody identification and development, validation, pre-clinical selection, licensing, and commercialization. Abcam also delivers recombinant protein engineering, synthesis, and production services at scale.
What is Abcam's geographic reach and customer base?
Abcam serves approximately 750,000 researchers across more than 130 countries. The company operates globally and maintains university-wide agreements with research institutions for antibody-based research products and life sciences reagents.
What recent initiatives is Abcam undertaking in AI-driven drug discovery?
Abcam joined the Innovative Health Initiative LIGAND-AI project, a public-private partnership led by the Structural Genomics Consortium and Pfizer with a budget exceeding €60 million. Through this five-year collaboration across nine countries, Abcam contributes expertise in recombinant protein engineering and production to generate high-quality protein-ligand datasets for training AI models to predict candidate molecules as suitable binders for thousands of human proteins.